



2024

Taipei International Breast Cancer Symposium

台北國際乳癌研討會

Speech Abstract

Topic:

Riding the Wave of Innovation: The evolving landscape of ADCs in Breast Cancer Treatment

Abstract

In recent years, antibody drug conjugates (ADCs) has demonstrated various breakthrough in different cancer types including breast cancer.

One of the most remarkable improvements is the survival extension in HER2+ breast cancer by novel HER2 ADC, trastuzumab deruxtecan. Besides in HER2+ subtype, another striking advance of this novel HER2 ADC is to prolong survival of breast cancer patients with tumors expressing lower level of HER2.

The latest evidence further demonstrated the potential of novel HER2 ADC in treating tumors with even lower level of HER2 (HER2 ultra-low), which drastically challenged the traditional categorization of breast cancers.

The new evidence mandated additional treatment choices for HER2-low / ultra-low patients. It also created more challenges on how to position this novel treatment, how to select patients suitable for this new treatment, how to deal with resistance to this new drug and how to sequence all available treatment choices with the consideration of maintaining patients' daily life quality.

In this talk, we will review the latest clinical evidence in HER2-low and ultra-low, treatment strategies in HR+ or in HR- BC patients, current understanding to the resistance mechanism to novel ADCs, ongoing studies to tackle the sequencing issue and emerging treatment in this area.